Monevue Monevue

Nyxoah S.A. NYXH 9.53 Nyxoah S.A.

Home
⇒ 
Stock List ⇒ Nyxoah S.A.
Range:4.0-20.0Vol Avg:60128Last Div:0Changes:0.1
Beta:0.6Cap:0.33BCurrency:USDExchange:NASDAQ
Sector:HealthcareIPO:Wed Apr 28 2021Empoloyees:146
CUSIP:CIK:0001857190ISIN:BE0974358906Country:BE
CEO:Mr. Olivier TaelmanWebsite:https://www.nyxoah.com
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Stock Details

Positive 0.31

Publication relating to transparency notifications

globenewswire.com·Tue Oct 15 2024
Positive 0.21

Publication relating to transparency notifications

globenewswire.com·Wed Oct 09 2024
Positive 0.30

Nyxoah Raises $27 Million through its At-the-Market Offering

globenewswire.com·Mon Oct 07 2024
Positive 0.13

Publication relating to transparency notifications

globenewswire.com·Fri Sep 27 2024
Monevue Monevue

About The Monevue

Stock News

Markets

Best Buys

The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
DMCA.com Protection Status • Powered by StackThrow